Piper Sandler Increases Replimune Group (NASDAQ:REPL) Price Target to $22.00

Replimune Group (NASDAQ:REPL – Get Free Report) had its price target upped by investment analysts at Piper Sandler from $14.00 to $22.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s target price suggests a potential upside of 128.45% from the stock’s previous close. […]

Leave a Reply

Your email address will not be published.

Previous post Tarsus Pharmaceuticals (NASDAQ:TARS) Coverage Initiated at Oppenheimer
Next post Nuveen California Quality Municipal Income Fund (NYSE:NAC) Sees Significant Growth in Short Interest